Skip to main
CRVO
CRVO logo

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 0%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed Inc. has demonstrated promising clinical data for its product candidate, Neflamapimod, particularly shown in the Phase 2b RewinD-LB trial, where a 32-week open-label extension yielded significant results reported in July 2025. The trial highlighted a substantial risk reduction of 64% (p=0.0001) among patients exhibiting minimal evidence of Alzheimer's disease co-pathology, suggesting a strong therapeutic potential for treating age-related neurologic disorders. Additionally, the contrast with placebo recipients, who experienced a mean increase in tau levels, further underscores the efficacy of Neflamapimod in improving synaptic functioning for affected patients.

Bears say

CervoMed Inc faces significant risks that contribute to a negative outlook on its stock, particularly related to its lead product candidate, Neflamapimod. Key concerns include the potential inability to establish an acceptable clinical development pathway for regulatory approval from the FDA, the prospect of generating non-positive data from pivotal trials, and the likelihood of slower market adoption post-approval. Furthermore, a discounted cash flow valuation methodology, which incorporates a 12% discount rate and a mere 40% probability of regulatory approval, highlights the financial uncertainty surrounding the company.

CervoMed Inc (CRVO) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 7 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.